Background
Data were reviewed on all types of calcium antagonFollowing the recent controversy in the medical and ists, including verapamil, diltiazem and the dihydlay press about the safety of calcium antagonists, the ropyridine drugs, such as nifedipine. Evidence was Liaison Committee of the World Health Organisation considered from a variety of sources including sysand the International Society of Hypertension fortematic overviews (meta-analyses) of randomised med an ad hoc subcommittee to review the relevant trials, individual randomised trials, non-randomavailable evidence about the effects of these agents ised trials and observational studies. Both published on the risks of coronary heart disease (CHD), cancer, and unpublished evidence was considered. Most of and bleeding. In July 1996, the subcommittee sought the evidence reviewed was from studies conducted submissions through notices in medical journals in patients with hypertension (with or without CHD) and through direct invitations to the authors of relor in patients with a history of myocardial infarction evant recent research reports and commentaries.
(with or without hypertension). Evidence was also sought directly from the published literature through computer searches of the
Methodological principles
Medline and Current Contents databases and through scrutiny of the reference lists of relevant In conducting this review, the subcommittee published papers. This report was drafted after acknowledged that the true effects of calcium antagreview of the available evidence and was issued by onists would be determined most reliably from data the subcommittee on 10 February 1997. in which both systematic errors (biases) and random errors (imprecision) were minimised. In this regard,
Scope of the report
the subcommittee was guided by the following general methodological principles that apply to the The primary objectives of this report were to conassessment of evidence about the effects of any sider systematically the available evidence about the medical intervention. effects of calcium antagonists on the risks of major CHD events (defined here as fatal or non-fatal myocardial infarction, or other death [sudden or not]
Minimisation of systematic errors from CHD) and of cancer (fatal or not). A secondary Systematic errors in estimates of treatment effect are objective was to review the available evidence about reduced in data from randomised controlled trials the effects of calcium antagonists on bleeding risks.
as a consequence of the random assignment of indiThese represent the main outcomes for which there vidual patients to study treatment and control is controversy about the effects of calcium antagongroups; randomisation minimises the likelihood of ists. Evidence about the effects of these agents on there being prognostically important differences other less frequent or less serious outcomes that between the groups at entry to the study. 1 Systemhave occasionally been reported to be associated atic errors are further reduced by basing estimates of treatment effect on a complete overview of the results of all relevant randomised trials, thereby reflect results of a non-representative subgroup of trials (eg, those that may be atypically positive or of estimates of treatment effect is greatest when large numbers of events are observed. Particularly large negative). 2 Data from trials in which the study treatment is allocated in a non-random manner, such as numbers of events are required for the reliable detection of small-to-moderate treatment effects. For comalternate patient allocation, can be affected by substantial systematic errors, particularly when the mon types of cardiovascular disease and cancer, the most plausible expectation about the effects of any investigator has foreknowledge of the treatment allocation schedule. 1 new treatment on major disease events is either no effect, modest harm or modest benefit.
1 Therefore The potential for systematic error is greatest, however, in observational studies of treatments selecdetermination of the most likely effects of calcium antagonists on the risks of major CHD events or cantively provided to individual patients when thought to be specifically indicated by the doctors responcer is likely to require studies in which large numbers of outcome events are observed. For example, sible for their care. In such studies, it is very difficult to distinguish differences in outcome that are the to detect a plausibly modest increase or decrease in risk of about one-fifth or one-sixth requires data consequence of the indication for treatment from differences in outcome that are conferred by the from a study (or an overview of studies) in which at least 1000 patients develop the relevant disease treatment itself. For example, some observational studies of patients following myocardial infarction during follow-up. While very large differences in disease frequency can be detected with many fewer reported increased mortality rates in those treated with digoxin, 3 but until recently 4 it was unclear observed cases, effects of such magnitude are unusual (particularly for widely prescribed drugs). whether this represented a true adverse effect of digoxin or the selection for treatment of higher-risk Where such effects have been detected, they are typically restricted to specific and infrequent outpatients (eg, those with heart failure or atrial fibrillation). 5 In general observational studies can comes, such as endometrial cancer in patients receiving unopposed oestrogen replacement therprovide useful evidence about the effects of a treatment only when these are both very large and apy 6 or angio-oedema in patients receiving an angiotensin-converting enzyme (ACE) inhibitor. 13 unlikely to be explained by known or unknown confounding due to indication. An example of such eviHence, while observational studies involving small numbers of cases may well suffice for the detection dence is the demonstration by observational studies of an approximately seven-fold increase in the risk of very large treatment effects, the reliable detection of more moderate effects (such as those that might of endometrial cancer in patients given long-term oestrogen-replacement therapy unopposed by progeplausibly be expected for calcium antagonists on CHD, cancer and bleeding risks) requires studies stogen. 6 In the assessment of more moderate effects or of outcomes likely to be substantively affected by involving both large numbers of cases and random assignment of treatments so that both random errors confounding, observational studies are less useful, since multivariate statistical adjustment is rarely and systematic errors are small in comparison with any effects of treatment. able to ensure that residual differences in outcome are not due to residual confounding by indication. For example, whereas overviews of randomised con-
Effects of calcium antagonists on CHD
trolled trials of both antihypertensive treatment 7, 8 risk and aspirin 9, 10 have clearly demonstrated that these treatments produce moderate reductions in the risks Blood pressure (BP) levels are directly and continuously related to the risks of initial major CHD of non-fatal myocardial infarction or CHD death, observational studies have reported increased risks events 14 as well as to the long-term risks of death from CHD after non-fatal myocardial infarction. 15 of CHD events among patients treated with antihypertensive drugs 11 or aspirin, 12 even after adjustSimilarly, BP levels are directly and continuously related to the risks of initial 14 and recurrent stroke. 16 ment for a variety of confounding factors. These misleading findings from observational studies seem Moreover, antihypertensive treatment with regimens based on diuretics or beta-blockers (but involving a likely to reflect persisting 'indication bias' in the observational studies, despite efforts to reduce conwide variety of other agents) has been shown in randomised trials to reduce the risks of major CHD founding through multivariate statistical adjustment. The failure of such statistical adjustment is events (both non-fatal myocardial infarction and deaths from CHD) as well as strokes in hypertensive due to both insufficient correction for recorded confounding factors (due to random errors in their patients with or without known CHD or cerebrovascular disease. 7, 8 Additionally, some agents that measurement) and lack of correction for confounding factors that were not recorded. The conselower BP have also been shown to reduce the risks of death and non-fatal myocardial infarction in quence of this is that observational studies may provide unreliable information, not just about the size patients with CHD, with or without hypertension. For example, there is strong evidence of this with of any treatment effect, but even about its direction.
beta-blockers, 17 and there is emerging evidence that long-term treatment with ACE inhibitors may have Minimisation of random errors similar effects. 18 On the basis of the foregoing, it would seem reasonable to expect that other BP-lowIn studies of disease risk, random errors are inversely proportional to the number of individuals ering drugs should also reduce the risks of CHD events, unless such drugs had specific adverse carobserved to develop the disease during follow-up. Thus, random errors are smallest, and the precision diac effects that offset the benefits of BP reduction.
Some pathophysiological mechanisms have been has been conducted in patients with a history of CHD (mostly myocardial infarction). Some of these proposed by which calcium antagonists may adversely affect the risks of CHD; these include protrials began treatment in the acute phase of myocardial infarction, while others started treatment later ischaemic, pro-arrhythmic, negative inotropic, hypotensive and reflex sympathetic effects. 19, 20 after infarction or among patients with stable angina. These trials fall into two main groups: trials However, the evidence is mixed as to whether calcium antagonists reliably produce such effects from a total of about 20 000 patients, among whom data on myocardial infarctions (some of which led to designed specifically to assess the effects of treatment on such outcomes. Some of these trials were death) were obtained from about 85%. [28] [29] [30] In these overviews, data on total mortality were obtained placebo-controlled studies of calcium antagonists 21, 22 (and T Zhang, personal communication) and from almost all patients, but CHD deaths were not analysed separately and no summary data are theresome compared the effects of calcium antagonists with other antihypertensive drugs. [21] [22] [23] [24] Most of the fore available about the effects of treatment on the overall risk of myocardial infarction or death from studies investigated the effects of long-acting dihydropyridine drugs. But, although these trials collec-CHD. In the studies contributing to these overviews, about 600 cases of myocardial infarction and 2000 tively involved a total of about 6000 patients, only about 50 cases of non-fatal myocardial infarction or deaths were observed during the scheduled period of treatment and follow-up (but with some 'doubledeath from CHD were observed during scheduled follow-up. Consequently, neither individually nor counting' of these events because, in several studies, myocardial infarctions followed by death were not in combination did these trials document sufficient CHD events for the reliable determination of any reported separately from myocardial infarctions with survival to the end of follow-up). plausible difference in risk between calcium antagonist and placebo groups or between calcium antagThe results of these overviews provide no clear evidence of an effect of calcium antagonists, cononist and other active treatment groups. So although CHD events were similarly distributed among calsidered collectively, on the risks of myocardial infarction or on overall mortality. Post hoc explocium antagonist and other active treatment and placebo groups in these trials, the results do not preration in subgroups of these trials did not find significant heterogeneity between the effects of the difclude real differences in outcome -in either direction -of moderate (or even large) magnitude. ferent individual agents. A non-significantly increased risk of myocardial infarction was observed Thus, the randomised trials of calcium antagonists in patients with hypertension provide little useful in patients assigned a dihydropyridine (odds ratio 1.19; 95% CI 0.92-1.53) and a marginally significant evidence from which to draw conclusions about the effects of these drugs on the risk of CHD. decreased risk was observed in patients assigned verapamil or diltiazem (odds ratio 0.79; 95% confiOne controlled trial of a long-acting formulation of nifedipine (which used alternate assignment to dence limits 0.67-0.94). These trends for myocardial infarction were mirrored by similar trends in total active treatment or placebo instead of proper random assignment) has recently been reported. 25 Howmortality (but these analyses are not independent of each other, for in some trials, cases of myocardial ever, in that study among 1632 Chinese patients, only four cases of myocardial infarction were infarction that led to death were included in both analyses). The greater apparent CHD risk in patients reported during 30 months of follow-up; strokes were less frequent among patients treated with assigned a dihydropyridine mainly reflected the results of trials of nifedipine, while the lower risk nifedipine (16 vs 36 strokes, relative risk 0.43; 95% CI 0.24 -0.77). A similar effect on stroke was also in patients assigned a non-dihydropyridine agent reflected similar trends in trials of treatment with observed in one of the randomised controlled trials conducted in China (14 strokes among patients verapamil and with diltiazem. But although this indirect comparison of the effects on CHD in trials of assigned nifedipine vs 28 among controls; relative risk 0.49; 95% CI 0.26-0.92) (T Zhang, personal dihydropyridine agents and those in trials of other calcium antagonists appeared to be conventionally communication), with very few strokes observed in the other randomised trials in hypertension.
significant (uncorrected P value 0.01), this comparison may have been inflated by chance and selection due to the post-hoc nature of the observation. In patients with coronary heart disease: A larger number of randomised trials of calcium antagonists Notably, the similar comparison for mortality was not statistically significant. Since publication of antagonist than in those assigned placebo (odds these overviews, a further randomised trial of veraratio 1.63; 95% CI 1.02-2.59). However, no data pamil in patients with a history of myocardial were given separately for myocardial infarction or infarction has been reported; 31 this trial produced CHD death, or for different types of calcium antagresults that were consistent with a beneficial effect onists. of verapamil on the risk of reinfarction, but they
The other group of randomised trials in patients were not by themselves definitive. The addition of with CHD directly compared the effects of calcium data from this study to the calcium antagonist trial antagonists vs beta-blockers. Two recent trials of overview strengthened slightly the evidence sugmoderate size 33, 34 have compared the effects of these gesting a beneficial effect of verapamil on the risks of drugs in patients with stable angina. Neither of these major CHD events (relative risk 0.81; 95% CI 0.67-studies showed any clear difference between agents 0.98), 30 but the selective addition of this trial alone in their effects on CHD risk, but once again these to the overview may have been influenced by its studies were too small (only about 100 CHD events results and could therefore be biased.
observed among 1500 patients) to detect plausible Further emphasis on this dihydropyridine vs nondifferences reliably between these treatments. dihydropyridine comparison subsequently led to an In summary, therefore, the results of all these analysis restricted solely to trials of nifedipine. 19, 20 trials of calcium antagonists in patients with CHD This involved data from about 10 000 patients in do not provide clear evidence of either a beneficial whom a total of about 750 deaths were observed.
effect or an adverse effect of these agents on the risk Analyses were restricted to all-cause mortality, and of major CHD events in patients with established separate analyses of myocardial infarction or death CHD. For although, in the placebo-controlled studfrom CHD were not provided. There was a slight ies, there is a trend towards a beneficial effect of excess of death (odds ratio 1.16; 95% confidence non-dihydropyridine agents on the risk of myocarlimits 1.01-1.33) among patients assigned treatment dial infarction and a trend towards an adverse effect with nifedipine. In the interpretation of this overof the dihydropyridine drugs studied (mostly IR view, emphasis was placed on the finding that most nifedipine), neither can be said to provide definitive of the apparent increase in risk was in trials evidence of an effect of calcium antagonists on overemploying very high doses of nifedipine (80 mg or all CHD risk. Nor are there any reliable data availmore per day). However, the number of events in able from trials in patients with CHD about the this subset of the trials is small (only 96 deaths in effects of the slow-release or long-acting dihydropyrtotal) and the hypothesis of an adverse effect of highidine calcium antagonists on the risk of major dose nifedipine represents the result of a series of CHD events. selective post-hoc decisions to focus, first on dihydropyridine drugs alone, second on nifedipine specifically, and then finally on doses of 80 mg or
In patients with heart failure: The other group of greater per day. (The hypothesis that higher doses trials that have provided evidence about the effects might be associated with greater risk was based on of calcium antagonists on CHD risk are those conobservational studies in which the observed risk ducted in patients with heart failure. There have was increased among patients taking more than the been two studies of moderate size and duration 35, 36 median dose of nifedipine [40 mg daily] . But, if 40 mg had been used to define high dose in the analysis and several smaller studies. The two larger studies of the randomised trials, then all of the trials would are placebo-controlled trials of newer dihydropyridhave been included in this category, and the findine agents (felodipine in one and amlodipine in the ings would have been far less striking.) Thus while other). Complete data on non-fatal myocardial the observation could be interpreted as an adverse infarction and fatal CHD events were not available dose-response relationship between nifedipine and from either trial; one study provided data on CHD the risk of death, the possibility that such a result deaths but not on non-fatal myocardial infarction could have been produced or exaggerated by dataand the other provided data on non-fatal myocardial dependent selection and the play of chance cannot infarction but not on CHD deaths The 36 CHD events be dismissed.
that were reported in total in these two studies were, A separate overview of 24 short-term (average durhowever, approximately evenly distributed between ation 10 weeks), placebo-controlled, randomised treatment and control groups. Clearly, however, the trials of a variety of different calcium antagonists in unavailability of complete data on major CHD patients with stable angina was conducted using all events, together with the small number of events of the data from safety and efficacy studies submitactually reported limit the ability of these trials to ted to the US Food and Drug Administration for detect plausibly modest increases or decreases in drug registration purposes. 32 These studies involved CHD risk with calcium antagonist treatment. One of a total of 1450 patients among whom about 80 were these studies did, however, observe an increase in withdrawn from treatment because of cardiovascuthe risk of pulmonary oedema among patients lar events (defined as increased or unstable angina, assigned treatment with amlodipine; 36 while there myocardial infarction, cardiovascular or unwitwas no evidence of such an increase in risk in the nessed death, ventricular tachycardia, other arrhythtrial of felodipine, 35,36 a smaller study of this drug mias, or other cardiovascular dropout). The likelireported an increase in treatment withdrawal due to hood of treatment withdrawal for these reasons was worsening heart failure. 37 somewhat greater in the patients assigned a calcium Observational studies use of hypertensive patients as controls will not necessarily avoid confounding by indication. While the statistical analyses of these studies included Case control studies: Three case control studies have reported data about the risks of myocardial adjustment for some potential confounding factors, this provides little reassurance that 'indication bias' infarction or death from CHD among hypertensive patients treated with a calcium antagonist. One of is not a plausible alternative explanation for the observed findings. Such statistical adjustment is these studies observed an increased CHD risk in patients treated with a calcium antagonist 38 and two likely to be incomplete due both to the error with which confounding factors (such as disease history did not. 39, 40 Among those not reporting an increase in risk, one included about 200 cases and 800 conor risk factor levels) were measured and to the limited number of potential confounding factors for trols 39 and the other included about 100 cases and 300 controls. 40 Both of these studies were too small which data were available (eg typically, little data were available about evidence of subclinical atheroto detect even a doubling in the risk of CHD with calcium antagonists. The case control study that sclerotic or myocardial disease that may affect prescribing patterns). Even comparisons of risk in reported an increase in risk involved about 600 cases and 2000 controls. 38 Among patients receiving patients treated with a calcium antagonist and patients treated with a beta-blocker may not be free treatment with a calcium antagonist, the risk of a major CHD event was about 60% greater than that of indication bias. Although both treatments may be selectively given to high risk patients (perhaps for observed in patients treated with other drugs. The increased risk primarily reflected a higher risk of the treatment of angina), there is no particular reason to expect that the average CHD risk (in the CHD events among those patients treated with a non-dihydropyridine calcium antagonist. This study absence of treatment) in patients treated with a calcium antagonist should necessarily be the same as also showed that patients receiving treatment with a calcium antagonist were more likely than others that in patients treated with a beta-blocker. Moreover, the suggestion of a dose-response association, to have a previous history of CHD or other risk factors, such as diabetes. The higher risk of CHD events while consistent with the hypothesis of a true adverse effect of calcium antagonists on CHD risk, among patients treated with calcium antagonists persisted after attempts to adjust for disease history could also be explained by the preferential use of higher doses of calcium antagonists in very high risk and risk factor profile. A further case control study has recently reported data about the risks of a variety patients, perhaps for the control of higher BPs 42 or more refractory angina. of cardiovascular events (but not CHD risks separately) among hypertensive patients treated with a calcium antagonist. 41 That study included about 200 cases and a similar number of controls, Cohort studies: An increased risk of CHD events among patients treated with a calcium antagonist and reported no overall increase in risk among individuals receiving treatment with a calcium antagonhas also been reported in an analysis of a small subgroup of about 900 participants from a prospective ist (odds ratio 0.89; 95% CI 0.45-1.75). However, while there was no evidence of increased risk among study of more than 10 000 elderly individuals. 43 The subgroup for which data were reported included patients treated with a long-acting calcium antagonist, an increased risk was observed among patients only patients treated with a single antihypertensive agent and excluded patients treated with multiple taking a short-acting calcium antagonist (odds ratio 3.98; 95% CI 1.18-13.89). However, the prevalence agents and other participants not receiving antihypertensive therapy. In this subgroup, there was a of prior cardiovascular disease was much higher among patients receiving treatment with a short-acttotal of about 50 CHD deaths observed during follow-up and, among those without a history of CHD, ing calcium antagonist (63%) than among those receiving treatment with a long-acting calcium there were only about 60 fatal and non-fatal CHD events in total. The distribution of these events sugantagonist (38%) or another non-calcium antagonist antihypertensive drug (21%). While an increased gested a several-fold greater risk of CHD events among those treated with nifedipine or with diltiarisk among patients treated with a short acting calcium antagonist was still evident among those zem (but not verapamil). As in some of the case control studies described above, patients treated with a patients without such a disease history, the extremely large size of the relative risk (12.4%) and calcium antagonist in this study population were likely to have a higher-risk medical history and a the small number of individuals treated with a short-acting calcium antagonist in this subgroup worse risk-factor profile than patients treated with other drugs. Although the increased risk persisted (nine cases and one control) raises concerns about the reliability of the result.
after controlling for some potential confounding factors, it is, once again, likely that the observed As discussed above in the section on Methodological principles, the major concern about such obserhigher risk of CHD events in patients treated with a calcium antagonist reflects, at least in part, the selecvational studies of treatment outcome is the large potential for systematic error to affect the results. It tion of higher risk patients for such treatment. The size of the risk observed among patients treated with is possible, indeed likely, that the decision to prescribe a calcium antagonist specifically for the treatcalcium antagonists in this study population is implausibly large, and inconsistent with the availment of high BP was frequently determined, at least in part, by factors associated with CHD risk (such as able results from randomised trials of calcium antagonists in patients with CHD. This underlines the disease history, age, risk factors levels). Thus, the magnitude of the biases that can affect such nontotal mortality referred to above 43 and so involving some of the same people, describe a somewhat randomised studies.
Three other cohort studies have recently reported greater incidence of cancer among patients receiving treatment with a calcium antagonist than among on the risk of all-cause mortality (but not specifically the risks of CHD events) among patients with a hisothers in the population studied. This cohort study involved a total of 5052 elderly individuals followed tory of CHD receiving treatment with calcium antagonists. In one study of 1200 patients with myocarfor 4 years. The first report was based on a total of 61 cases of cancer, 27 of which occurred among dial infarction, 44 overall mortality rates appeared to be higher among patients treated with either nifedippatients treated with calcium antagonists. The second report was based on a total of 420 cases, 47 ine or verapamil. In another study of about 11 000 patients with established CHD, half of whom were of which occurred among patients treated with a calcium antagonist. Thus neither report from this study treated with calcium antagonists (half with nifedipine and one-third with diltiazem), there was no clear involved sufficient cancer cases to characterise reliably any plausibly modest association between increase in risk associated with calcium antagonist treatment. 45 Once again, however, in both these calcium antagonist use and overall cancer risk. Moreover, the two reports do not provide indestudies there was evidence that patients treated with calcium antagonists tended to have a worse medical pendent evidence about the association, since it appears that the cancer cases included in the first history and/or risk factor profile than did others, and the possibility that either of the results could have analysis were also included in the second, and in the report based on the larger number of cases, the been importantly affected by confounding is, again, not easily dismissed. Most recently, a report on 7 observed increase in the crude rate of cancer among calcium antagonist-treated patients was of only boryears of follow-up in the Framingham Study provided no evidence of increased mortality among 400 derline statistical significance (P value 0.03). Multivariate adjusted analyses of the data suggested a hypertensive patients (half with a history of CHD) treated with a calcium antagonist. 46 greater increase in cancer risk with calcium antagonist use (adjusted odds ratio 1.72; 95% CI 1.27-2.34). This increase in risk was observed in patients Effects of calcium antagonists on cancer treated with either nifedipine or verapamil, but did risk not appear to reflect an increase in any one type of In some cohort studies, a modest direct association cancer (or subgroup of related cancers). As in some between BP levels and the overall risk of death from of the observational studies of CHD, there also cancer has been reported. 47 However, analyses based appeared to be a direct association between the dose on the totality of evidence from a large number of of calcium antagonist used and risk. It was suggested cohort studies have not demonstrated such an that these findings could be explained by a cancerassociation (Prospective Studies Collaboration, promoting effect of calcium antagonists, mediated unpublished data). While complete data on cancer perhaps by inhibition of apoptosis. While there is incidence are not available from the earlier trials of evidence that calcium antagonists can inhibit experantihypertensive treatment, those studies have demimentally-induced apoptosis, 51, 52 and increase the in onstrated no change in the risk of death from nonvitro growth of certain human cancer cell lines, 48 vascular causes among patients assigned active other data on the effects of calcium antagonists on treatment, mostly with diuretic-or beta-blockerapoptosis and growth in a tissue with increased probased regimens. 7, 8 Similarly, no complete or reliable liferation indicate stimulation of apoptosis and inhidata on cancer incidence are available either from bition of proliferation. 53 the more recent randomised trials of calcium antagAs in the observational studies of calcium antagonists in patients with hypertension or from the onists and CHD, confounding by indication is also trials of calcium antagonists in patients with CHD. a plausible alternative explanation for the findings A review by the US Food and Drug Administration in this study of calcium antagonists and cancer. At (Albert DeFelice, personal communication) of all the entry to the study, there was evidence of a more freavailable evidence concerning rodent tumorigenicquent history of ill health among patients taking a ity concluded that there was no evidence of any calcium antagonist. Although the increased risk of direct carcinogenic effect of any registered calcium cancer persisted after controlling for some aspects antagonist in any of several strains of both rats and of medical history and a few other relevant factors mice, and no indication of genotoxicity in a variety that had been recorded (such as smoking, alcohol of bacterial and mammalian cells calibrated with consumption and body mass index), for reasons known mutagens. While there has been a report that given above and elsewhere, 54 such analyses cannot verapamil increased the in vitro growth of human fully exclude confounding by indication as an altercolon and breast cancer cell lines, 48 the main connative explanation. Residual confounding would be cerns about possible adverse effects of calcium consistent with the observation that the association antagonists on cancer risk have arisen primarily was not with just one or a few types of cancer, but from the results of some observational studies of of a generalised increase in most cancer types. Estabpatients treated with a calcium antagonist.
lished exogenous causes of cancer typically affect particular sites selectively, and the apparently broad Observational studies association of calcium antagonist use with cancer risk in this study population could be explained by Two reports 49, 50 from part of the same parent cohort as the smaller study on calcium antagonist use and more frequent use of these agents among sicker patients generally, including some whose symptoms GI bleeding (42 bleeds: relative risk 1.86; 95% CI 1.22-2.82) and of severe GI bleeding (31 bleeds: relawere the consequence of undiagnosed cancer. Moreover, the apparent absence of the usual latent period tive risk 1.68; 95% CI 1.03-2.74). Surprisingly, this was similar to the excess risk observed with aspirin between exposure and cancer development is also atypical of established exogenous causes of cancer, use (relative risk 1.5) and with oral anticoagulants (relative risk 2.2). This apparent increase in any GI and would once again suggest that residual confounding may be an explanation.
bleeding was observed with the use of diltiazem (18 bleeds: relative risk 2.18; 95% CI 1.24 -3.82) and It has also been observed that sicker patients -as were the patients treated with a calcium antagonist verapamil (13 bleeds: relative risk 2.39; 95% CI 1.28-4.44) but not with nifedipine (9 bleeds: relain this study -are typically less likely to relocate than others who are in better health. 54 For this reative risk 1.04; 95% CI 0.51-2.13).
A similar, though non-significant, increase in the son it is possible that there may be a bias towards the less frequent detection not only of cancers but risk of GI bleeding was also observed with calcium antagonist use (odds ratio 1.87; 95% CI 0.79-4.41) also of other conditions (such as myocardial infarction) among healthier individuals. Additionin a study of 73 cases and 73 age-and sex-matched controls; however, in that study 70-80% of patients ally, sicker patients could be more likely to receive diagnostic investigations that uncover malignancies, treated with calcium antagonists were using nifedipine. 58 By contrast with these studies, a large comand this could also introduce detection bias, particularly over the short duration of these studies. Both parison of outcome between 2248 calcium antagonist-treated patients undergoing cardiac surgery and these sources of detection bias could result in a spurious apparent increase in risk among sicker 2909 cardiac surgery patients not receiving calcium antagonists did not indicate any increases in transpatients, such as those receiving treatment with a calcium antagonist.
fusions (about 200 in total: 3% on calcium antagonist vs 5% not) or reoperations for bleeding (about One case control study of colon cancer has recently reported an extreme increase in risk among 100: 1% vs 2%); indeed, there were significant trends towards fewer such bleeds with calcium patients treated with verapamil but not with other calcium antagonists. However, only 11 patients in antagonist use. 59 Similarly, in a small series of 120 patients undergoing coronary artery graft surgery, the entire study population reported taking this drug. 55 In the cohort study described above there calcium antagonist use was not associated with any increases in post-operative bleeding or transwas no significant increase in colon cancer among patients receiving treatment with any calcium antagfusions. 60 onist, and separate data were not provided about the risk in patients receiving verapamil.
Randomised trials
In patients with coronary heart disease: Most ran-
Effects of calcium antagonists on
domised trials of calcium antagonists in patients bleeding risk
with CHD have not specifically provided data on bleeding. But, review of the published reports of It has been suggested that calcium antagonists might several of the larger randomised controlled trials of cause bleeding by inhibiting platelet aggregation calcium antagonist use -involving a total of over while also preventing the normal vasoconstrictive 15 000 patients with an average follow-up of about response to bleeding. 56 A randomised placebo-con-11 months (ie, about 14 000 patient-years of trolled trial of the dihydropyridine drug, nimodiptreatment) 26,27,31,36,61-63 -indicates that no bleeding ine, was stopped prematurely after 149 of a schedexcess was reported in any of these controlled trials, uled 400 patients undergoing cardiac valve although detailed reasons for discontinuing study replacement had been recruited, due to a few more treatment were given. This lack of any reported deaths having been observed among those allocated bleeding risk in these large randomised trials does nimodipine (8/75 [11%] vs 1/74 [1%]). 57 As major not seem to be consistent with the excess risk of GI bleeding during and after surgery appeared to occur bleeding of about one case per 100 patient-years of often in that study, analyses of bleeding were perforcalcium antagonist treatment estimated from the med which indicated an excess of major bleeding first of the observational studies described. 56, 64 with nimodipine (10 [13%] vs 2 [3%]; P value 0.03). Subsequently, four observational studies explored In patients with cerebrovascular disease: Calcium the associations between calcium antagonist use and antagonists have been assessed extensively in ranbleeding. 56, [58] [59] [60] domised controlled trials among patients in whom any adverse effects on bleeding would have been Observational studies expected to be particularly obvious -for example, in the immediate management of subarachnoid The first of these was a cohort study that included a total of 120 individuals with gastrointestinal (GI) haemorrhage and acute ischaemic stroke. In the management of subarachnoid haemorrhage, the calbleeds, of which 47 were considered to be severe, among a total population of 1636 individuals aged cium antagonists that have been most widely studied in randomised trials are the dihydropyridines 68 or older taking beta-blockers, calcium antagonists or ACE inhibitors for any indication. 56 Compared (in particular nimodipine), and these have usually been started as soon as possible after the initial with beta-blocker use, the use of any calcium antagonist was associated with an increased risk of any bleed. A meta-analysis of six randomised placebo-controlled trials of 3-12 weeks of nimodipine in ope and the USA, calcium antagonists are prescribed for a smaller but still substantial proportion over 1200 such patients indicated a reduction in the incidence of 'poor outcome' (ie, dead/vegetative/ of patients with high BP. The major objectives of antihypertensive treatment in these populations are severely disabled), 65 and in the largest of these studies, among over 500 patients, it was explicitly the prevention of both stroke and CHD events. However, at the present time, data on the effects of calreported that there was no excess of any adverse effect such as increased rebleeding. 66 Studies of cium antagonists on stroke and CHD are available from only four small randomised trials in patients other calcium antagonists in acute subarachnoid haemorrhage have been much smaller, although with hypertension, and even in aggregate the data from these trials do not provide reliable information larger studies are in progress that might help further to resolve any remaining concerns about bleeding about effects on these important outcomes of treatment. There are more data on CHD events from trials with calcium antagonist use.
In acute ischaemic stroke, both anticoagulant and in patients with myocardial infarction or angina, but overviews of the results from these trials do not fibrinolytic therapies have been shown to be associated with haemorrhagic transformation and intracershow a clear overall effect of calcium antagonists on the risks of myocardial infarction or death from any ebral bleeds, leading to a poor outcome, so trials of calcium antagonists in this setting might be cause. Selective emphases on subgroups of trials with particular agents suggest the possibility of expected to be especially useful for demonstrating (or refuting) the sort of hazards due to bleeding that modestly beneficial effects of diltiazem and verapamil and modestly adverse effects of nifedipine. But have been suggested by the results of some observational studies. A meta-analysis has been reported these trends were not strong, and could well be biased -both in favour of and against particular involving nine randomised placebo-controlled trials in which a total of about 3700 stroke patients were agents -as a consequence of the retrospective manner in which they were identified. The limited inforallocated 2-4 weeks of 120 mg daily oral nimodipine or control. 67 Overall in this overview there was mation available from trials of calcium antagonists in patients with heart failure adds little to the assessno evidence of any adverse effects of calcium antagonist use on death or clinical deterioration; indeed, ment of the effects of these agents on the risk of CHD. subgroup analyses suggested improved outcome with nimodipine among those treated within 12 Although the data on CHD risk from randomised trials of calcium antagonists are limited, they do hours of symptom onset, albeit with an opposite trend among those treated after 24 h. But, in a more exclude the possibility of adverse effects of the extreme magnitude suggested in reports from some recent trial of nimodipine 120 mg daily in 350 acute ischaemic stroke patients there did not appear to be observational studies. For example, the upper confidence limit of the estimated effect of nifedipine in any improvement in functional outcome, even among those treated within 12 h, and mortality was randomised trials in patients with CHD includes an adverse effect of 30-50%. This is substantially less significantly increased at 1 and 3 months. 68 Data on bleeding were not explicitly reviewed in the metathan the 60-300% increases in risk suggested by some observational studies of hypertensive patients, analysis and there were no bleeds reported in the more recent trial, but more detailed consideration of underlining the very large potential for bias in such studies, and suggesting that their results may be larsuch information in each of these trials (along with that in trials of other calcium antagonist regimens) gely, if not wholly, due to confounding rather than to drug effects. There is clear evidence from several might provide an opportunity to assess any haemorrhagic complications of calcium antagonists in this studies that calcium antagonists are preferentially prescribed to the sickest patients, including those setting of high bleeding risk. Selective emphasis on apparent increases (or decreases) in bleeding in just with CHD and other high-risk conditions such as diabetes, and it is unlikely that statistical adjustone or other of these stroke studies may, however, be biased as the studies that report such information ment for confounding can remove this source of bias entirely. may have extreme results.
The available evidence does not prove the existence

Summary and conclusions
of either beneficial or harmful effects of calcium antagonists on the risks of major CHD events, Calcium antagonists are used extensively throughout the world for the treatment of high BP and including fatal or non-fatal myocardial infarctions and other deaths from CHD. This applies to the eviangina. In Japan, they are prescribed for about threequarters of all treated hypertensive patients 69 and in dence on all calcium antagonists considered collectively, and to that on subgroups of these agents. China, calcium antagonists (mostly short-acting agents) are prescribed for about one-half of all such patients (L Liu, personal communication). In these Evidence about the effects of calcium antagonists on the risk of cancer is derived almost entirely from Far East countries, the main objective of antihypertensive treatment is the prevention of stroke, since observational studies, since no reliable data have been reported on this outcome from randomised the risks of CHD are very much lower. For this reason, the concerns that have been raised about the trials. In this situation, it is particularly difficult to test the validity of reports from some observational effects of calcium antagonists -particularly the short-acting agents -on CHD risk are less relevant studies suggesting an increased cancer risk among patients treated with a calcium antagonist. The to their use in the Far East than in the West. In Eur-observed increases in cancer risk could reflect a and randomised trials does not provide clear evidence of an adverse effect of calcium antagonists on chance occurrence, systematic error or a true adverse effect of these agents. The very small numbleeding risks. bers of cancer cases on which the findings of increased risk were based and the modest level of Two major issues are raised by the findings of this review. The first is the clear failure of pharmaceutstatistical significance are consistent with chance being an explanation. The results may well also ical companies, regulatory authorities and clinical researchers to ensure the timely conduct of studies have been affected by confounding by indication, since patients in poor health appear to be given calthat could provide clinicians and patients with reliable evidence about both the safety and efficacy cium antagonists more frequently than other antihypertensive drugs. Detection bias may also have of widely prescribed calcium antagonists. Such assurance requires studies in which both random occurred, with adverse outcomes more likely to be detected among those prescribed calcium antagonand systematic errors are minimised concurrently, and this can only be provided by large-scale ranists, who as a consequence of their poorer state of health may be both less likely to relocate and more domised trials. A number of such trials are now underway, some of which were ongoing at the time likely to receive diagnostic procedures. The possibility of residual confounding, even after statistical concerns about the safety of calcium antagonists were raised, and some of which were initiated in adjustment, is consistent with the observation that the increased risk appears to be distributed widely direct response to the controversy. By early in the next decade, data should be available from trials across cancer subtypes, as well as between other distinctly different disease entities (including gastroinvolving about 100 000 patients with hypertension randomised to treatment with a calcium antagonistintestinal haemorrhage 56 and Parkinson's disease
70
). While a biological mechanism has been suggested based regimen or a diuretic/beta-blocker-based regimen. About half of these patients will be in trials of to account for the increased cancer risk in patients treated with a calcium antagonist, this is highly the newer slow-release or long-acting dihydropyridine agents, and the remainder will be in trials of speculative and controversial, 71 and adds little to the strength of the evidence relating calcium antagnon-dihydropyridine drugs. These studies should be able to determine reliably whether such calcium onist use to cancer incidence. In particular, it is inconsistent with the evidence from animal studies antagonist-based regimens have any importantly different effects on CHD and major bleeding risks from demonstrating no carcinogenicity of any calcium antagonist approved for use in the USA. In considerthose conferred by diuretic-or beta-blocker-based regimens. Long-term follow-up of patients in these ing the evidence about cancer risk, there is cause to reflect on earlier reports from observational studies trials beyond the scheduled treatment period could also provide useful information about the effects of raising concerns about a possible adverse effect of reserpine, [72] [73] [74] another BP lowering drug, on breast these agents, if any, on cancer risk. Such large-scale studies of efficacy and safety should routinely be cancer risk. The observation was subsequently shown to be the consequence of confounding. 75 initiated early in the development of new drug classes that are destined to be marketed for the treatOther reports of an increased cancer risk associated with atenolol 76 and enalapril 77 remain unconfirmed, ment of common cardiovascular diseases. Only in this way will controversies of the kind that has but they too seem likely to have been the consequence of chance and selective post hoc emphasis.
involved calcium antagonists be avoided in the future. 78, 79 Howent pattern of hazard. Instead, excesses of bleeding associated with calcium antagonist use observed in ever, the results of previous observational studies of medical interventions indicate that unless the some small observational studies and randomised trials have not been observed in some other, larger, observed effect of treatment is very large, the results of such studies do not provide a reliable guide to studies that have addressed this issue. Moreover, calcium antagonists have been carefully studied in the size, or even the direction, of the real treatment effects. This is probably, in large part, due to concertain circumstances where the risks associated with bleeding are high, and yet no excesses of severe founding by indication, but it may also reflect detection bias and publication bias. It is quite possible bleeds or adverse outcome due to bleeding were reported. So, although it is not possible to rule out that there are a number of other observational studies with data on both calcium antagonist use and modest effects of calcium antagonists on bleeding, the available evidence does not seem to be consistcardiovascular and cancer outcomes that remain unpublished. Since negative findings are less likely ent with the large haemorrhagic risk (ie, similar to that associated with oral anticoagulants) that has to be published than positive findings, 80 it is questionable whether the currently available data are been suggested by some investigators.
representative of the totality of the observational data potentially available.
The available evidence from observational studies
In conclusion, the available evidence about the They were chosen to represent a range of experience, viewpoints and geographic regions. In order effects of calcium antagonists on the risks of CHD, cancer and bleeding does not establish the existence for readers of this review to take account of any potential conflicts of interest among members of the of beneficial or harmful effects. This conclusion has few implications for current guidelines about the subcommittee, each member was asked to declare relevant financial interests including research suptreatment of hypertension, since most already acknowledge the absence of reliable randomised eviported by pharmaceutical companies*, current consultancies for such companies , and shares in any dence about the effects of calcium antagonists on major morbidity and mortality. For the treatment of such companies. Details of all such interests have been provided to the Liaison Committee of the angina, the results of this review similarly do not provide any strong reason to change recommenWorld Health Organisation and International Society of Hypertension. No committee member dations. However, they do underline the large differences that exist in the strength of the evidence availheld shares in any pharmaceutical company, a few held consultancies, and most received support for able about the effects of different classes of BP lowering drugs on major health outcomes. For research from a variety of companies. Subcommittee members: Michael Alderman* patients with hypertension, there is now very strong evidence from randomised trials that treatment regi-(New York), Kikuo Arakawa (Fukuoka), Lawrie Beilin* (Perth), John Chalmers* (Sydney), Jay Cohn* mens involving diuretics or beta-blockers (in combination with a wide variety of other older antihyper-(Minneapolis), Rory Collins* (Oxford), Robert R Fenichel (Washington), Edward D Frohlich* (New tensive agents) are effective in reducing the risks of major CHD events and stroke, with no effect Orleans), Pavel Hamet* (Quebec), Lennart Hansson* (Uppsala), Charles Hennekens* (Boston), Emilio detected on major non-vascular causes of death (of which there were, in aggregate, several hundred) Kuschnir (Cordoba), Liu Lisheng* (Beijing), Stephen MacMahon* (Auckland), Giuseppe Mancia* (Milan), during the 5-year average duration of these trials. 7, 8 For patients with a history of myocardial infarction, Ingrid Martin (Geneva), Joel Menard* (Paris), Peter Sleight* (Oxford), Judith Whitworth (Sydney), there is strong evidence from randomised trials that treatment with a beta-blocker reduces the risks of Salim Yusuf* (Hamilton), Alberto Zanchetti* (Milan). death and re-infarction, 17 and in the presence of left ventricular dysfunction or heart failure, there is Writing committee: Stephen MacMahon, John Chalmers, Rory Collins, with the assistance of Bruce clear evidence from randomised trials of beneficial effects of ACE inhibitors on overall mortality and Neal (Auckland). heart failure-related morbidity, 81 and emerging evidence of benefit for major CHD events. 18 However, Sponsorship for other patient groups (including those with
The activities of this subcommittee were underhypertension), there is still no direct evidence of written by the International Society of Hypertension benefit from ACE inhibitors for major CHD events or and were sponsored by several non-commercial for stroke. By contrast, there is little or no reliable organisations including the British Heart Founevidence from randomised trials of beneficial (or dation, the Canadian Hypertension Society, the harmful) effects of calcium antagonists on major carFoundation for High Blood Pressure Research diovascular morbidity and mortality in any patient (Australia), the High Blood Pressure Research Coungroup. For, although the trends for verapamil and cil of Australia, the Medical Research Council of diltiazem in patients with a history of myocardial Canada, the Metabolic Disease Foundation of Japan, infarction are suggestive of benefit and the trends for the National Health Committee of New Zealand, the nifedipine are suggestive of harm, selective emphaNational Health and Medical Research Council of sis on these subgroups of agents was largely retroAustralia, the National Heart Foundation of Ausspective and the trends could therefore be inflated tralia and the Swedish Society of Hypertension. No (or produced entirely) by chance and selection.
pharmaceutical company provided support for the Hence they require confirmation in further trials.
activities of this subcommittee. For other newer agents, such as alpha-blockers and angiotensin-II antagonists, there is no evidence 
